Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
Galabova G, Brunner S, Winsauer G, Juno C, Wanko B, Mairhofer A, Lührs P, Schneeberger A, von Bonin A, Mattner F, Schmidt W, Staffler G. Galabova G, et al. Among authors: schneeberger a. PLoS One. 2014 Dec 4;9(12):e114469. doi: 10.1371/journal.pone.0114469. eCollection 2014. PLoS One. 2014. PMID: 25474576 Free PMC article.
Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines.
Mandler M, Santic R, Gruber P, Cinar Y, Pichler D, Funke SA, Willbold D, Schneeberger A, Schmidt W, Mattner F. Mandler M, et al. Among authors: schneeberger a. PLoS One. 2015 Jan 22;10(1):e0115237. doi: 10.1371/journal.pone.0115237. eCollection 2015. PLoS One. 2015. PMID: 25611858 Free PMC article.
Vaccination for Parkinson's disease.
Schneeberger A, Mandler M, Mattner F, Schmidt W. Schneeberger A, et al. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S11-3. doi: 10.1016/S1353-8020(11)70006-2. Parkinsonism Relat Disord. 2012. PMID: 22166404 Review.
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, Galabova G, Majbour N, Vaikath N, El-Agnaf O, Winter D, Mihailovska E, Mairhofer A, Schwenke C, Staffler G, Medori R. Volc D, et al. Among authors: schneeberger a. Lancet Neurol. 2020 Jul;19(7):591-600. doi: 10.1016/S1474-4422(20)30136-8. Lancet Neurol. 2020. PMID: 32562684 Clinical Trial.
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.
Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, Adame A, Schmidhuber S, Santic R, Schneeberger A, Schmidt W, Mattner F, Masliah E. Mandler M, et al. Among authors: schneeberger a. Mol Neurodegener. 2015 Mar 19;10:10. doi: 10.1186/s13024-015-0008-9. Mol Neurodegener. 2015. PMID: 25886309 Free PMC article.
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.
Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, Schneeberger A, Mattner F, Masliah E. Mandler M, et al. Among authors: schneeberger a. Acta Neuropathol. 2014;127(6):861-79. doi: 10.1007/s00401-014-1256-4. Epub 2014 Feb 14. Acta Neuropathol. 2014. PMID: 24525765 Free PMC article.
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
Meissner WG, Traon AP, Foubert-Samier A, Galabova G, Galitzky M, Kutzelnigg A, Laurens B, Lührs P, Medori R, Péran P, Sabatini U, Vergnet S, Volc D, Poewe W, Schneeberger A, Staffler G, Rascol O; AFF009 Study Investigators. Meissner WG, et al. Among authors: schneeberger a. Mov Disord. 2020 Nov;35(11):1957-1965. doi: 10.1002/mds.28218. Epub 2020 Sep 3. Mov Disord. 2020. PMID: 32882100 Free PMC article. Clinical Trial.
196 results